bapineuzumab

Bapineuzumab is a humanized monoclonal IgG1 antibody developed as a passive immunotherapy for Alzheimer's disease. It specifically targets the N-terminal region (Aβ1–5) of amyloid beta (Aβ) peptides, binding both fibrillar and soluble forms. By binding to Aβ, bapineuzumab is designed to promote clearance of amyloid plaques from the brain through activation of microglial phagocytosis and cytokine production. Preclinical studies demonstrated reduced plaque burden and improved synaptic function in animal models. In clinical trials, bapineuzumab lowered biomarkers such as amyloid brain plaque and phosphorylated tau protein in cerebrospinal fluid but did not show significant cognitive benefit in patients with mild-to-moderate Alzheimer's disease. The drug was investigated primarily for intravenous administration but development was discontinued after phase III trials failed to meet primary efficacy endpoints[1][3][4][5][6][7].

Other names

bapineuzumab